Oncolytics Biotech Inc. (ONCY)

[onco_investor]

ONCY Appoints Senior VP, Global Licensing and Business Development

CALGARY, Dec. 11 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development
"Dr. Warrander will be responsible for the execution of the global licensing strategy for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "Having reached an agreement on the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers with the U.S. Food and Drug Administration under the Special Protocol Assessment (SPA) process, and with ongoing Phase 2 studies in multiple indications, we felt it was important to bring this skill set in house."

In his 32-year career, Dr. Warrander has held a number of positions within the biotechnology and pharmaceutical industries. He held a number of progressively senior positions in the pharmaceutical industry, most recently as Director, Global Licensing, AstraZeneca. Dr. Warrander subsequently served as Senior Vice President, Life Sciences at Wood Mackenzie, providing partnering support and advice to a range of clients on licensing, merger and acquisition and financing projects globally. Most recently, as an independent consultant, he has worked with a number of biotechnology clients including Oncolytics, serving as a director of Oncolytics Biotech (Barbados) Inc. He holds a PhD from the Department of Biochemistry at the University of Birmingham and a BSc in Chemistry and Biochemistry from the University of St. Andrews